196 related articles for article (PubMed ID: 33323991)
1. Antihypertensive effects and safety of esaxerenone in patients with moderate kidney dysfunction.
Ito S; Itoh H; Rakugi H; Okuda Y; Iijima S
Hypertens Res; 2021 May; 44(5):489-497. PubMed ID: 33323991
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of dosage-escalation of low-dosage esaxerenone added to a RAS inhibitor in hypertensive patients with type 2 diabetes and albuminuria: a single-arm, open-label study.
Itoh H; Ito S; Rakugi H; Okuda Y; Nishioka S
Hypertens Res; 2019 Oct; 42(10):1572-1581. PubMed ID: 31239535
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of esaxerenone (CS-3150), a newly available nonsteroidal mineralocorticoid receptor blocker, in hypertensive patients with primary aldosteronism.
Satoh F; Ito S; Itoh H; Rakugi H; Shibata H; Ichihara A; Omura M; Takahashi K; Okuda Y; Iijima S
Hypertens Res; 2021 Apr; 44(4):464-472. PubMed ID: 33199881
[TBL] [Abstract][Full Text] [Related]
4. Long-term phase 3 study of esaxerenone as mono or combination therapy with other antihypertensive drugs in patients with essential hypertension.
Rakugi H; Ito S; Itoh H; Okuda Y; Yamakawa S
Hypertens Res; 2019 Dec; 42(12):1932-1941. PubMed ID: 31554937
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of esaxerenone (CS-3150) for the treatment of essential hypertension: a phase 2 randomized, placebo-controlled, double-blind study.
Ito S; Itoh H; Rakugi H; Okuda Y; Yamakawa S
J Hum Hypertens; 2019 Jul; 33(7):542-551. PubMed ID: 31113987
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of esaxerenone (CS-3150) in Japanese patients with type 2 diabetes and macroalbuminuria: a multicenter, single-arm, open-label phase III study.
Ito S; Kashihara N; Shikata K; Nangaku M; Wada T; Okuda Y; Sawanobori T
Clin Exp Nephrol; 2021 Oct; 25(10):1070-1078. PubMed ID: 34110524
[TBL] [Abstract][Full Text] [Related]
7. Esaxerenone (CS-3150) in Patients with Type 2 Diabetes and Microalbuminuria (ESAX-DN): Phase 3 Randomized Controlled Clinical Trial.
Ito S; Kashihara N; Shikata K; Nangaku M; Wada T; Okuda Y; Sawanobori T
Clin J Am Soc Nephrol; 2020 Dec; 15(12):1715-1727. PubMed ID: 33239409
[TBL] [Abstract][Full Text] [Related]
8. Exploratory study on the relationship between urinary sodium/potassium ratio, salt intake, and the antihypertensive effect of esaxerenone: the ENaK Study.
Katsuya T; Inobe Y; Uchiyama K; Nishikawa T; Hirano K; Kato M; Fukui T; Hatta T; Iwasaki A; Ishii H; Sugiura T; Taguchi T; Tanabe A; Sugimoto K; Shimosawa T;
Hypertens Res; 2024 Apr; 47(4):835-848. PubMed ID: 38212366
[TBL] [Abstract][Full Text] [Related]
9. Synergistic reduction in albuminuria in type 2 diabetic mice by esaxerenone (CS-3150), a novel nonsteroidal selective mineralocorticoid receptor blocker, combined with an angiotensin II receptor blocker.
Arai K; Morikawa Y; Ubukata N; Sugimoto K
Hypertens Res; 2020 Nov; 43(11):1204-1213. PubMed ID: 32616846
[TBL] [Abstract][Full Text] [Related]
10. Double-Blind Randomized Phase 3 Study Comparing Esaxerenone (CS-3150) and Eplerenone in Patients With Essential Hypertension (ESAX-HTN Study).
Ito S; Itoh H; Rakugi H; Okuda Y; Yoshimura M; Yamakawa S
Hypertension; 2020 Jan; 75(1):51-58. PubMed ID: 31786983
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and Safety of Esaxerenone in Hypertensive Patients with Diabetic Kidney Disease: A Multicenter, Open-Label, Prospective Study.
Uchida HA; Nakajima H; Hashimoto M; Nakamura A; Nunoue T; Murakami K; Hosoya T; Komoto K; Taguchi T; Akasaka T; Shiosakai K; Sugimoto K; Wada J;
Adv Ther; 2022 Nov; 39(11):5158-5175. PubMed ID: 36070133
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and Safety of Esaxerenone in Hypertensive Patients with Left Ventricular Hypertrophy (ESES-LVH) Study: A Multicenter, Open-Label, Prospective, Interventional Study.
Yamamoto E; Usuku H; Sueta D; Suzuki S; Nakamura T; Matsui K; Matsushita K; Iwasaki T; Sakaino N; Sakanashi T; Hirayama K; Kurokawa H; Kikuta K; Yamamoto N; Sato K; Tokitsu T; Taguchi T; Shiosakai K; Sugimoto K; Tsujita K;
Adv Ther; 2024 Mar; 41(3):1284-1303. PubMed ID: 38310194
[TBL] [Abstract][Full Text] [Related]
13. Safety and efficacy of esaxerenone in Japanese hypertensive patients with heart failure with reduced ejection fraction: A retrospective study.
Iwahana T; Saito Y; Okada S; Kato H; Ono R; Kobayashi Y
PLoS One; 2021; 16(11):e0259485. PubMed ID: 34748605
[TBL] [Abstract][Full Text] [Related]
14. Antihypertensive Effect of Long-Term Monotherapy with Esaxerenone in Patients with Essential Hypertension: Relationship Between Baseline Urinary Sodium Excretion and Its Antihypertensive Effect.
Ichikawa S; Tsutsumi J; Sugimoto K; Yamakawa S
Adv Ther; 2022 Oct; 39(10):4779-4791. PubMed ID: 35976603
[TBL] [Abstract][Full Text] [Related]
15. [Pharmacological profile, clinical efficacy, and safety of esaxerenone (Minnebro
Yamakawa S; Homma T; Yamada M; Igawa Y; Yoshimura M
Nihon Yakurigaku Zasshi; 2020; 155(5):340-350. PubMed ID: 32879177
[TBL] [Abstract][Full Text] [Related]
16. Effects of the novel nonsteroidal mineralocorticoid receptor blocker, esaxerenone (CS-3150), on blood pressure and urinary angiotensinogen in low-renin Dahl salt-sensitive hypertensive rats.
Li L; Guan Y; Kobori H; Morishita A; Kobara H; Masaki T; Nakano D; Nishiyama A
Hypertens Res; 2019 Jun; 42(6):769-778. PubMed ID: 30587856
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and Safety of Esaxerenone (CS-3150) for the Treatment of Type 2 Diabetes with Microalbuminuria: A Randomized, Double-Blind, Placebo-Controlled, Phase II Trial.
Ito S; Shikata K; Nangaku M; Okuda Y; Sawanobori T
Clin J Am Soc Nephrol; 2019 Aug; 14(8):1161-1172. PubMed ID: 31248950
[TBL] [Abstract][Full Text] [Related]
18. Single- and multiple-dose escalation study to assess pharmacokinetics, pharmacodynamics and safety of oral esaxerenone in healthy Japanese subjects.
Kato M; Furuie H; Shimizu T; Miyazaki A; Kobayashi F; Ishizuka H
Br J Clin Pharmacol; 2018 Aug; 84(8):1821-1829. PubMed ID: 29688582
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and Safety of Esaxerenone in Hypertensive Patients with Diabetes Mellitus Undergoing Treatment with Sodium-Glucose Cotransporter 2 Inhibitors (EAGLE-DH).
Motoki H; Inobe Y; Fukui T; Iwasaki A; Hiramitsu S; Koyama S; Masuda I; Sekimura N; Yamamoto K; Sato A; Komatsu M; Taguchi T; Shiosakai K; Sugimoto K; Kuwahara K
Adv Ther; 2023 Nov; 40(11):5055-5075. PubMed ID: 37733211
[TBL] [Abstract][Full Text] [Related]
20. Esaxerenone, a novel nonsteroidal mineralocorticoid receptor blocker (MRB) in hypertension and chronic kidney disease.
Wan N; Rahman A; Nishiyama A
J Hum Hypertens; 2021 Feb; 35(2):148-156. PubMed ID: 32661269
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
